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INTRODUCTION
Autoimmune thyroid diseases (AITD) present with two
pathogenetically different diseases: Hashimoto’s thyroiditis
(HT) and Graves’ disease (GD). These two are clinically di-
verse and taken together make thyroid condition the com-
monest autoimmune disease. However, there is significant
geographic variation in the worldwide reported incidence
and prevalence of HT and GD. AITD prevalence is about
5% in the overall population, whereas the prevalence of thy-
roid antibodies is estimated to be 10–20% of all women
(Hollowell et al., 2002; Pyzik et al., 2015). The worldwide
incidence of HT is reported to be 0.3–1.5 cases per 1000
persons per year (Latina et al., 2013). Furthermore, HT is
the most common cause of primary hypothyroidism in
iodine-sufficient regions. Like most autoimmune disorders
AITD exhibits a strong female bias in prevalence: HT af-
fects women five to ten times more (Pyzik et al., 2015), and
GD four to five times more often than men (Carlé et al.,
2011). It is also known that the prevalence of thyroid auto-
immunity increases with age reaching the highest number of
cases between 45–65 years in HT and between 33–50 years
in GD (Cooper and Stroehla, 2003).
The prevalence and incidence of autoimmune diseases, in-
cluding AITD, has increased significantly over the last dec-
ades. AITD has become a public health problem worldwide,
including in Latvia. In our previous study of iodine defi-
ciency during pregnancy, it was revealed that 10.7% of the
739 pregnant women participating nationwide had elevated
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Autoimmune thyroid diseases (AITD) mainly include Hashimoto’s thyroiditis (HT) and Graves’ dis-
ease (GD), which are characterised by the presence of circulating antibodies against various thy-
roid autoantigens and infiltration of the thyroid gland by autoreactive lymphocytes. Despite the
significant advancement in the knowledge of AITD pathogenesis in the last decade, the specific
immunological mechanisms responsible for development of the disease are not thoroughly under-
stood. Classically, HT has long been considered as a T helper (Th)1-mediated disease, while a
Th2-driven autoimmune response is dominant for GD development. However, this classification
has changed due to the description of Th17 lymphocytes, which suggested participation of these
cells in AITD, particularly HT pathogenesis. Moreover, a shift in the balance between Th17 and T
regulatory (Treg) cells has been observed in thyroid autoimmunity. We have observed overex-
pression of IL-17, the prominent effector cytokine of Th17, within thyroid tissues from HT and GD
patients in our studies. The present review will focus on recent data regarding the role of Treg
and Th17 lymphocytes in AITD pathogenesis. In addition, the impact and proposed mechanisms
of the predominant environmental factors triggering the autoimmune response to the thyroid will
be discussed.
Key words: Hashimoto's thyroiditis, Graves disease, T helper 17 cell, T regulatory cell, environ-
mental factors.
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thyroperoxidase antibody (TPOAb) levels suggesting preex-
isting thyroid autoimmunity (Konrade et al., 2015). Further-
more, data on thyroid medicinal product use trends from the
Latvian National Health Service and State Agency of Medi-
cines showed a steady increase in the number of people us-
ing thyroxine and thiamazole: thyroid therapy defined daily
dose (DDD) per 1000 inhabitants increased from 10.23 in
2009 to 17.40 in 2017, thereby extremely increasing disease
burden on health, health costs, education, society and family
life (Anonymous, 2018).
AITD are characterised by the presence of circulating anti-
bodies against thyroid autoantigens and infiltration of the
thyroid gland by autoreactive lymphocytes (Tomer, 2014).
Interestingly, although TPOAb and thyroglobulin antibodies
(TgAb) are detected in 90–95% and 70–80% of AITD pa-
tients, respectively, the prevalence of both antibodies in pa-
tients with non-thyroid immune diseases is 10–15% (Car-
valho et al., 2013). HT results predominantly from the
cellular immune response, which involves T helper (Th)1
and Th17 cells and leads to cell death of the thyrocytes with
subsequent hypothyroidism, whereas GD mainly promotes
Th2-related humoral autoimmunity causing production of
TSH receptor (TSHR) antibodies and growth of the thyro-
cytes leading to the development of hyperthyroidism (Mor-
shed et al., 2012). However, both thyroid disorders may co-
exist in the same individual causing mixed Th1/Th2/Th17
immune responses.
Various environmental and endogenous factors may act to-
gether to trigger thyroid autoimmunity in persons with pre-
disposing genetic variants causing elevated thyroid autoan-
tigen presentation and a loss of immune tolerance. Despite
numerous studies undertaken and knowledge accumulated
on the aetiology and pathogenesis of AITD in the last dec-
ade, the specific immunological mechanisms responsible for
development of the disease are not thoroughly understood.
GENETIC SUSCEPTIBILITY
The role of genetic background in the aetiology of AITD is
highlighted by numerous epidemiological studies showing
that genetic factors contribute in about 70–80% cases the
development of thyroid autoimmunity (Tomer and Davies,
2003; Hansen et al., 2006). The familial clustering of AITD
was confirmed by several studies 50 years ago. It has been
shown later that almost 50% of the siblings of GD patients
have thyroid autoantibodies and that 33% of those with HT
or GD develop AITD themselves (Villanueva et al., 2003).
Increased familiar clustering of AITD has been reported in
German study indicating a 32-fold enhanced risk for devel-
oping HT in children and a 21-fold enhanced risk in siblings
of patients with HT (Dittmar et al., 2011).
During the last decades, a number of twin studies have ex-
amined the aetiology of several phenotypes related to AITD
and have provided new data on the genetic contribution to
AITD. A strong influence of genetic factors on the develop-
ment of AITD has been demonstrated by twin studies as
well — the heritability of GD and thyroid autoantibody
(TPOAb and TgAb) formation has been reported to be 79%
and 73%, respectively (Brix et al., 2001; Hansen et al.,
2006). A study of Hashimoto’s hypothyroidism showed
55% and 0% concordance in Danish monozygotic and dizy-
gotic twins, respectively, indicating an essential role of en-
vironmental factors in development of the disease (Brix et
al., 2000). Thus, twin studies have shown that 21–27% of
the total phenotypic variance in AITD can be explained by
environmental factors.
Therefore, it is critical to investigate and identify the possi-
ble interplay of environmental and genetic factors involved
in thyroid autoimmunity to propose individualised AITD
management strategies, since most environmental factors
may be modified. However, the mechanisms by which the
environmental factor trigger thyroid autoimmunity in indi-
viduals with known susceptibility loci remain unclear. The
main known susceptibility genes for AITD can be classified
as either immunoregulatory or thyroid-specific genes
(Effraimidis and Wiersinga, 2014). TSHR and Tg were re-
cognised as thyroid-specific genes, whereas the human leu-
kocyte antigen (HLA), PTPN22, CTLA-4, FOXP3, FCRL3,
CD25, CD40, and other genes as immune-modulating, play-
ing a critical role in the development of the effective im-
mune response including self-tolerance, and cell-mediated
and humoral immunity. However, single nucleotide
polymorphisms in these genes, which are not specific for
AITD were recognised as risk factors for other autoimmune
diseases (Lee et al., 2015). Tg is one of the main thyroid
autoantigens assumed as a major susceptibility gene for
AITD (Tomer et al., 2002). Whereas in GD patients, a con-
sistent association with polymorphisms of the TSHR gene
was reported (Xiong et al., 2016).
The occurrence of both AITD is associated with specific
variants of the HLA class II genes. They are vital for regu-
lating immune activity by determining the antigen binding
specificity and the initiation of the immune response. HLA
controls cytokine production and modulates the immune re-
sponse by cytokine genes on haplotypes as well. Thus,
polymorphisms in the HLA genes may lead to HT or GD
via regulating the Th1/Th2 and possibly Th17 pathways.
HLA-DQA1 and HLA-DR3 were shown to be associated
with GD, while polymorphisms in HLA-DR3, DR4, DR5,
DQ7, DQB1, DQA1, DQW7 were correlated with the inci-
dence of HT (Zeitlin et al., 2008; Badenhoop et al., 1990).
Numerous susceptibility genes and loci for AITD have been
detected by genome-wide association studies (GWAS) dur-
ing the last decade. However, these studies involve mainly
single genetic factors, which might have a minor effect on
the disease development and only the simultaneous pres-
ence of certain genetic and environmental factors altogether
may lead to the clinical manifestation of the thyroid
autoimmunity. Therefore, GWAS should focus on simulta-
neous investigation of multiple genetic and environmental
factors and interactions between them.
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PROTECTION AGAINST THYROID AUTOIMMUNITY
Mechanisms of central and peripheral tolerance provide
proper regulation of the immune system thus protecting
against thyroid autoimmunity. Maturation of T helper CD4+
lymphocytes occurs in the thymus via processes of positive
and negative selection. Central immune tolerance refers to
apoptosis of autoreactive T cells in the thymus during the
foetal life. T cells that escape negative selection are pre-
vented from triggering autoimmunity by mechanisms of pe-
ripheral tolerance where T regulatory cells (Treg) play a
crucial role (Weetman, 2010; Shevach, 2006). Their protec-
tive role has been also demonstrated in several animal mod-
els of autoimmune diseases (Morris et al., 2009).
Treg cells derive from the thymus as a subpopulation of
fully differentiated T cells (thymus-derived Treg), naive
Th0 cells in the peripheral tissues (peripheral differentiated
Treg) or develop in vitro conditions (iTregs) (Shevach and
Thornton, 2014). The first properly characterised Treg cell
subset exhibits expression of the transcription factor
forkhead box protein 3 (Foxp3) and high constitutive levels
of á chain of the IL-2 receptor (CD25). Foxp3 contributes to
the maintenance of self-tolerance by promoting develop-
ment of Treg while inhibiting the differentiation of Th17
cells (González-Amaro and Marazuela, 2016). Foxp3 muta-
tions in humans can cause an allotropic syndrome of
multi-organ autoimmunity such as IPEX (immune
dysregulation, polyendocrinopathy, enteropathy, X-linked)
syndrome. Several studies evidenced a defective function of
Foxp3+ Treg cells in patients with HT and GD (Glick et al.,
2013).
Treg cells have been shown to suppress target cells by di-
rect cell-to-cell interaction or secretion of inhibitory
cytokines such as transforming growth factor  (TGF-),
interleukin (IL)-10, and IL-35. IL-10 induces suppression of
pathogenic Th17 cell responses and maintains Treg suppres-
sive activity and expression of Foxp3, TGF- regulates dif-
ferentiation, proliferation and survival of lymphocytes,
while the exact role of IL-35 requires further investigation
(Chaudhry et al., 2011; Huber et al., 2011).
Another subset of Treg cells recently described demon-
strates constitutive expression of CD69 but does not express
Foxp3 or CD25. These cells exert their immunosuppressive
activity mainly through the production of IL-10 and TGF-
(Han et al., 2009). Interestingly, increased levels of CD69+
Treg cells were found in both peripheral blood and thyroid
tissue of AITD patients. However, these lymphocytes were
dysfunctional and unable to effectively down-modulate the
autoimmune process and tissue damage, thus suggesting
their role in the pathogenesis of autoimmune diseases
(Rodríguez-Muñoz et al., 2016). Finally, Foxp3- IL-10 se-
creting type 1 regulatory (Tr1) cells have been shown to in-
hibit T cell activity by different mechanisms, such as inhibi-
tory cell-cell interactions via cytotoxic T lymphocyte
antigen-4 (CTLA-4) or programmed cell death protein-1
(PD-1) and secretion of granzyme B and perforin
(Roncarolo et al., 2014).
Several studies have found decreased frequency and/or a
defective function of Treg in patients with HT or GD (Li et
al., 2016) and highlighted the essence of results previously
observed in animal models. Although the number of Treg
cells reported is variable due to use of different detection
markers and estimations related to disease stages, the major-
ity of studies suggest that the reduction or functional defects
of Treg is tightly associated with the development of thy-
roid autoimmunity. Recently, a possible role of regulatory B
cells (Breg) in the maintenance of peripheral tolerance and
inhibition of immune responses to specific self-antigens via
release of IL-10, TGF-, Fas ligand, and tumour necrosis
factor (TNF)-related apoptosis inducing ligand has been es-
tablished as well (Kristensen et al., 2015). Thus, both Treg
and Breg cells may act as inhibitors of inflammatory and
autoimmune responses to prevent autoimmunity. In certain
individuals, however, autoreactive T lymphocytes escape
from the control of these immunoregulatory mechanisms
and may lead to loss of the peripheral self-tolerance with
subsequent development of autoimmune disease via activa-
tion, proliferation and differentiation. Reduction of periph-
eral self-tolerance occurs due to enhanced Th17 cell re-
sponse as compared with induced regulatory Th10 cell
response (Papp et al., 2017).
PATHOGENESIS OF AITD
Thyroid autoimmunity appears as a result of the breakdown
or reduction of self-tolerance to the three major thyroid pro-
teins — TPO, TG, and TSHR occurring in the central or pe-
ripheral organs of the immune system. This causes the infil-
tration of the thyroid gland by T and B lymphocytes
followed by production of AITD specific antibodies, induc-
tion of the thyrocyte apoptosis and the gland destruction in
HT. Although traditionally the pathogenesis of HT is due to
T cell-mediated autoimmunity and GD is a result of humo-
ral autoimmunity, cellular and humoral immune responses
are closely connected and cross-linked (Ramos-Leví and
Marazuela, 2016). Despite comprehensive research in the
last decades, the exact mechanisms of initiation and pro-
gression of thyroid autoimmunity have not been completely
established.
The genetic background, self-antigens, and various environ-
mental triggers together determine features of the autoim-
mune response in AITD and cause the enhanced thyroid an-
tigen presentation and reduction of immune tolerance.
Antigen-presenting cells (APC), and especially dendritic
cells colonising the thyroid gland, present specific thyroid
antigens to T lymphocytes via the MHC complex in the
lymph nodes. This results in activation and proliferation of
autoreactive T and B lymphocytes, and production of differ-
ent cytokines by immune and thyroid cells. In fact, dendritic
cells may be functionally subdivided into two groups —
immunogenic or tolerogenic — depending on the activation
of autoreactive T-cells or Treg, respectively (Maldonado
and von Andrian, 2010). Moreover, several studies have re-
vealed increased levels of dendritic cells within inflamma-
tory infiltrates of the thyroid in both GD and HT patients
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(Roura-Mir et al., 2005; Mao et al., 2011). Once activated,
T helper (CD4+) cells can be differentiated into at least four
main functional subsets according to the production of spe-
cific cytokines — Th1, Th12, Th17, and Treg. The develop-
ment of the Th1 population is stimulated in the presence of
either IL-12 or interferon (IFN)- through transcription of
T-bet, whereas differentiation of Th2 cells is driven by IL-4
via the master transcription factor GATA3 (Peck and
Mellins, 2010).
Classically, HT has long been considered as a Th1-mediated
disease, while a Th2-driven autoimmune response is domi-
nant for GD development. However, this classification has
changed due to the description of Th17 cell, which sug-
gested an evident participation of these cells in AITD, and
particularly HT pathogenesis. In HT, increased Th1 activity
caused by upregulation of pro-inflammatory cytokines such
as IL-2, IL-1b, IFN-, TNF- leads to cell-mediated immu-
nity and thyrocyte death in apoptotic pathways. Thus,
autoreactive Th1 cells recruit CD8+ cytotoxic T cells,
which cause thyrocyte apoptosis by action of granzyme and
perforin. In addition, autoreactive T lymphocytes induce an-
tibody production by B cells leading to necrosis of thyroid
cells by complement system activation. Finally, thyrocytes
can undergo caspase-mediated apoptotic death in a para-
crine way by expression of the CD95/Fas death receptor
(Fröhlich and Wahl, 2017). Although the contribution of
anti-TPO antibodies to destruction of the thyroid gland
compared to cytotoxicity is minor, autoantibodies have
shown pathogenic effects including complement activation
and induction of oxidative stress, indicating that HT is also
a Th2-mediated disease. Moreover, it has been revealed that
anti-TPO antibodies can cause damage of cultured thyroid
cells performed upon binding to TPO located on the apical
cell membrane via both antibody-dependent cytotoxicity
and complement-dependent cytotoxicity (Rebuffat et al.,
2008).
In GD, there are increased levels of Th2 released cytokines
IL-4, IL-5, IL-6, IL-10, IL-13, which mainly mediate humo-
ral response by stimulating production of TSH receptor an-
tibodies, growth of the thyrocytes and apoptosis of the thy-
roid gland infiltrating lymphocytes via downregulation of
Fas/Fas ligand and upregulation of the anti-apoptotic mole-
cule Bcl-2 (Berger, 2000; Salmaso et al., 2002). Also, anti-
bodies to TPO and, less frequently, to Tg have been identi-
fied in most GD patients. Furthermore, TPO and Tg
autoantibodies may comprise immunoglobulin (Ig) G4 as
well as IgG1 subclasses, suggesting the participation of
both Th2 and Th1 cytokines in GD.
During the last decade, a role of a new subset of Th cells,
designated Th17, has been studied in the pathogenesis of
thyroid autoimmunity, thus changing the traditional para-
digm of Th1/Th2 dichotomy. Several research groups have
shown that IL-17A, the prominent effector cytokine of
Th17, can induce the release of different pro-inflammatory
cytokines responsible for induction and development of
chronic inflammatory responses in many autoimmune dis-
eases including AITD.
TH17 CELLS AND THYROID AUTOIMMUNITY
The discovery of a third Th subset has introduced a new un-
derstanding of the classical Th1 and Th2 dichotomy. Th17
cells and their hallmark cytokine IL-17 were found to play
an important role in the pathogenesis of different inflamma-
tory and autoimmune diseases, which were previously clas-
sified as Th1-dependent pathologies. An altered balance be-
tween Th17 and Treg cells as well as Treg cell dysfunction
has been found in autoimmune diseases (Papp et al., 2017).
Previous studies have shown a significant increase of Th17
cells and IL-17, revealed in the peripheral blood and thyroid
tissues of AITD patients when compared to control subjects,
suggesting their contribution to thyroid autoimmunity. Li
and colleagues revealed an increased number of thyroid tis-
sue infiltrating Th17 cells and serum levels of IL-17 in pa-
tients with HT compared to the thyroid cancers, nodular
goiters or healthy controls. Additionally, a strong associa-
tion between IL-17 expression and stromal fibrosis was ob-
served in HT patients (Li et al., 2017). Furthermore,
Figueroa-Vega et al. observed enhanced levels of Th17
cells and IL-17 mRNA in peripheral blood and thyroid tis-
sue infiltrating inflammatory cells in patients with HT,
along with higher levels of IL-6, IL-15, and IL-23, which
are involved in the Th17 cell differentiation (Figueroa-Vega
et al., 2010). Later, Konca Degertekin and colleagues found
that hypothyroid patients had lower levels of IL-17 and IL-
23 than in euthyroid HT patients, suggesting that hypothy-
roidism itself has an inhibitory effect on Th17 cytokine re-
sponses (Konca Degertekin et al., 2016). Less is known
about participation of Th17 cells and their cytokines in the
pathogenesis of GD. Previous studies showed an enhanced
number of CD4+IL-17+ cells in the peripheral blood of
children with untreated HT, but not in GD patients (Bos-
sowski et al. 2012). Similarly, IL-17 levels in the peripheral
blood and thyroid tissues did not differ significantly be-
tween adult patients with GD and controls (Qin Q et al.,
2012). An increased expression of IL-17 within thyroid tis-
sues from HT and GD patients was found also in our study
(Zake et al., 2018). We observed stronger immunoexpres-
sion level of IL-17A in thyroid follicular cells in HT and
GD patients when compared to patients with colloid goiter,
thus suggesting that Th17 cells had an essential role in
AITD pathogenesis (p < 0.001 and p = 0.007, respectively)
(Fig. 1).
Graves’ orbitopathy (GO), a serious and most frequent
extrathyroidal complication of GD, manifests as orbital in-
flammation and expansion of adipose tissue and extraocular
muscles. Several studies have investigated the involvement
of Th17 cells in the pathogenesis and disease activity of
GO. Serum IL-17 levels were found to be significantly
higher in GO patients than in controls. Patients with active
GO had higher serum concentrations of IL-17 compared to
inactive GO patients. Furthermore, IL-17 levels were corre-
lated with clinical activity score of GO, thus supporting the
role of IL-17 in the pathogenesis and progression of GO
(Kim et al., 2012). Fibrosis and adipogenesis are the two
dominant pathophysiologic orbital processes involved in the
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pathogenesis of GO. Recently, Fang and colleagues re-
ported enhanced levels of pathogenic IFN- and IL-22–pro-
ducing Th17 cells in active GO patients, compared to inac-
tive GO patients and controls (Fang et al., 2017).
Additionally, a positive correlation between pathogenic
Th17 cells and clinical activity score of GO was observed,
indicating that the number of these cells might serve as an
indicator of GO severity and activity. The authors also dem-
onstrated that Th17 lymphocytes can promote proinflam-
matory cytokine production in both CD90+ (favour fibrosis)
and CD90– (favour adipose hyperplasia) orbital fibroblasts
and stimulate costimulatory molecule expression on orbital
fibroblasts that are CD34+. Moreover, both orbital
fibroblast subsets can directly induce naive T cell differenti-
ation toward the Th17 phenotype via prostaglandin E2 pro-
duction (Fang et al., 2017).
Th17 cells are mainly characterised by the production of
IL-17A and IL-17F responsible for the development of in-
flammation, particularly in autoimmune diseases. They can
act on epithelial cells, fibroblasts, and macrophages, induc-
ing the release of pro-inflammatory mediators such as
cytokines (IL-6, IL-8, TNF-, IL-1, GM-CSF, G-CSF),
chemokines (CXCL1, CXCL8, CCL2, CCL7, CCL20), and
metalloproteinases (Song et al., 2014). IL-17 regulates dif-
ferentiation of immune cells within the germinal centre of
the lymphoid follicle and autoantibody production. It has
been found that IL-17 stimulates neutrophil recruitment by
inducing CXCL8 by both immune and non-immune cells.
As mentioned above, different cytokines and transcription
factors are required for regulating naïve Th lymphocyte dif-
ferentiation into a Th1, Th2, Th17 or Treg cell subset (Fig.
2). In contrast to convincing experimental data highlight-
ing Th17 cell development, only a few human studies per-
formed in the past have established the cytokine pattern in-
volved in the generation of Th17 cells (Peck and Mellins,
2010; Stritesky et al., 2008). In fact, the cytokine profile
necessary for driving the differentiation of Th17 lympho-
cytes is similar in both humans and mice. TGF-, along
with the proinflammatory cytokines such as IL-1, IL-6,
IL-21, and IL-23, have been found to have an essential role
in the development of Th17 cells. It has been found that
Th17 lineage is directed by their master transcription factor
retinoic acid receptor-related orphan nuclear receptor
gamma (ROR), which is induced by IL-6 and IL-23 via
signal transducer and activator of transcription 3 (STAT3).
Interestingly, TGF- is important for the differentiation of
both Th17 and induced Treg cells. It has been shown that
high doses of TGF- induce expression of Foxp3, thus pro-
moting Treg differentiation, while low doses of TGF- in
combination with IL-6 promote Th17 polarisation
(Stadhouders et al., 2018). In mice, the combination of
IL-6, IL-1, and IL-23 has been found to be sufficient for
the differentiation of Th17 cells, indicating TGF- inde-
pendent signalling of Th17 development. Th17 cells were
also found colonising the gut of TGF- signalling-deficient
mice (Qin et al., 2009). In contrast to mice observations,
TGF- seems to be indispensable for the differentiation of
Th17 cells in man. Thus, TGF- in the presence of IL-6 and
IL-21 induces the initial differentiation of Th17 from naïve
Th cells, while IL-23 and IL-1 are essential for both com-
plete maturation and stabilisation of the Th17 population
(naïve Th cells do not express IL-1 and IL-23 receptor)
(Stritesky et al., 2008). Although IL-23 is not required for
the induction of Th17 development, it is a crucial factor for
the stabilisation and generation of the pathogenic phenotype
of Th17 cells via STAT4 (Croxford et al., 2012). IL-23,
produced by dendritic cells and macrophages, can maintain
Th17 cell differentiation by suppressing IL-10 secretion and
promoting IL-22 and GM-CSF production.
Fig. 1. (A) IL-17 positivity demonstrated in the follicular epithelial cells in HT patient (x400). Confocal microscopy, representative image of IL-17 positive
thyrocytes: green staining shows IL-17-specific staining, blue staining shows nuclei, insert (x1000). (B) Weak IL-17 immunoreactivity in GD patient (x250).
(C) Colloid goiter with almost nil IL-17 expression (x400).
Fig. 2. Th17 subsets and their cytokines. Adapted from “A cellular and mo-
lecular view of T helper 17 cell plasticity in autoimmunity” by R.
Stadhoudersab, E. Lubberts, R.W. Hendriks, J. Autoimmun., 2018, 87,
1–15.
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Although the Th17 subset was identified more than a de-
cade ago, it has become clear only recently that Th17 cells
are heterogeneous and not uniform in function, exhibiting
under certain cytokine exposure two different cellular phe-
notypes: pathogenic and non-pathogenic (Stadhouders et
al., 2018). Th17 cells differentiated in the presence of
TGF-1 and IL-6 co-produce IL-17 and IL-10. These cells
are assigned to the non-pathogenic subset of the Th17-lin-
eage, as they do not induce tissue inflammation and may in-
hibit an autoimmune inflammation. By contrast, Th cells
upon exposure to IL-23, IL-1, and IL-6 can generate
highly pathogenic Th17 lymphocytes, which drive the auto-
immune inflammation (Ghoreschi et al., 2010). These
pathogenic lymphocytes can secrete both common and
pathogenic sets of molecules, such as IL-17A/F, IL-21,
IL-22, IL-26, IFN-, TNF, and GM-CSF (Stadhouders et
al., 2018). Enhanced levels of IL-23 were observed in the
peripheral blood and within thyroid tissues of HT patients
but it still remains unclear whether IL-23 is involved in the
pathogenesis of GD. Recently, when studying the immuno-
expression of IL-23 and IL-1 within thyroid tissue of
AITD subjects, we found that expression of both inter-
leukins was significantly increased in HT patients compared
to GD and colloid goiter patients, but no difference was
found between the expression level of interleukins in pa-
tients with GD and colloid goiter (unpublished data).
Cytokines play a crucial role in modulating immune re-
sponse in both AITD. Cytokines produced by activated T
cells may drive the autoimmune response skewing toward
the Th17 phenotype and away from Th1 or Th2 phenotypes.
Therefore, evaluation of T cell subsets linked to certain cy-
tokine production in AITD could help to identify the main
immunological mechanisms involved in thyroid autoimmu-
nity thus deepening our knowledge about disease outcome
and treatment strategies. Th17 cells exhibit various thera-
peutic targets, and treatment strategies include blockade of
the differentiation of Th17 cells, inhibition of Th17 neutral-
ising cytokines, and Th17-specific transcription factors
(Maddur et al., 2012). Furthermore, several IL-17 neutralis-
ing monoclonal antibodies, such as secukinumab, ixekizu-
mab and brodalumab, have been developed in recent years,
which have demonstrated impressive therapeutic effects in
patients suffering from psoriasis (McInnes et al., 2015).
Further experimental and clinical studies are needed to bet-
ter clarify the role of different Th subsets in AITD.
ENVIRONMENTAL FACTORS
Increased iodine intake appears as the most important
among environmental factors studied and is suggested as in-
fluencing the development of AITD. Other suggested risk
factors include selenium deficiency, smoking, alcohol,
stressful life events, infections, several drugs, and exposure
to chemical compounds. Prevention of iodine deficiency
disorders by food iodine fortification has been successfully
implemented in many countries in the past century. How-
ever, other preventive interventions for AITD may be com-
plicated or even impracticable. It would be extremely im-
portant to recognise which preventive interventions can be
taken by subjects with a risk to develop AITD. Excess io-
dine intake and a relative selenium deficiency appear to be
the predominant environmental factors triggering the auto-
immune response to the thyroid.
Iodine intake. Iodine intake contributes to thyroid function
and the development of thyroid gland disorders. The recom-
mended daily allowance of iodine for adults is 150 µg, in-
creasing to 250 µg in pregnancy and lactation. It is well
known that iodine-sufficient populations compared to those
that are iodine-deficient appear to have higher incidences of
thyroid-specific antibodies and autoimmune hypothy-
roidism. Data from epidemiological studies show that, due
to reduced synthesis of thyroid hormone, severe iodine defi-
ciency may develop revealing the increased prevalence of
goiter and hypothyroidism, whereas chronic mild-to-moder-
ate iodine deficiency may cause toxic nodular goiter and
hyperthyroidism (Zimmermann and Boelaert, 2015). By
contrast, chronic excessive iodine intake or a rise in usual
intake, especially after the implementation of mandatory
food iodine fortification (e.g. universal salt iodisation), may
lead to the increased prevalence of thyroid autoimmunity
and subclinical hypothyroidism in parallel with a decrease
in rates of iodine deficiency-related thyroid disorders (Teng
et al., 2006). Thus, the prevalence of TPOAb in the Danish
population before and 4–5 years after a cautious mandatory
iodisation of salt aiming to adjust iodine intake to a low rec-
ommended level was 14.3% and 23.8%, respectively
(Pedersen et al., 2011). Furthermore, the rise in the fre-
quency of thyroid antibodies was most pronounced in
women aged 18–45. Five to seven years after iodine fortifi-
cation, the overall incidence rate of overt hypothyroidism
increased as well, reaching 47.2/100 000 per year compared
to 38.3/100 000 per year at baseline (Pedersen et al., 2007).
In the Pescopagano survey in Italy, introduction of the salt
iodisation programme 15 years later resulted in increased
prevalence of TPOAb (12.6% vs 19.5%) and also HT rates
(3.5% vs 14.5) (Aghini Lombardi et al., 2013). However, it
has been also shown that the optimisation of nutritional io-
dine intake may result in lowered incidence of autoimmune
thyroiditis. After implementation of mandatory fortification
of salt with iodine in Brazil in 1956, adjustments of the io-
dine concentration in salt were performed in 2003 and 2013
by decreasing the recommended iodine concentration to
20–60 and 15–45 mg per kg of salt, respectively. A
cross-sectional study conducted in 2013 demonstrated a
trend toward a decreased prevalence of HT and a decrease
in urinary iodine concentration to optimal levels. (Miranda
et al., 2015). However, it is unclear what will be the impact
of a new continuing reduction in salt iodine concentration
on thyroid function. The first systematic review and
meta-analysis regarding the effect of excess iodine intake
on thyroid disease prevalence in different populations,
which was published recently, indicated that although uni-
versal salt iodisation decreased goiter rates, chronic excess
iodine intake from water or poorly monitored salt was a risk
factor for hypothyroidism in free-living populations
(Katagiri et al., 2017). Therefore, accurate monitoring of io-
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dine concentration both in salt and water is required for pre-
vention of thyroid disorders.
The mechanisms by which increased chronic intake of di-
etary iodine contributes to thyroid autoimmunity are not
completely understood. In susceptible individuals, iodine
excess induces thyroid gland infiltration by lymphocytes
liberating cytokines and chemokines, thus leading to gener-
ation of thyroid antibodies. Moreover, high iodine intake
enhances Th17 and inhibits Treg cell differentiation, while
it triggers an abnormal expression of TNF-related
apoptosis-inducing ligand in thyrocytes, thereby inducing
cell death of thyroid cells (Yu et al., 2011). It has been
shown recently that excess iodine promotes apoptosis of
thyroid follicular epithelial cells seen in HT by inhibiting
autophagy activity. This process is mediated through
TGF-1 downregulation and activation of the Akt/mTOR
signaling pathway. In addition, excess iodine increases pro-
duction of reactive oxygen species contributes to oxidative
stress and thyrocyte apoptosis (Xu et al., 2016). Excessive
iodine may also alter the conformation of TG and promote
its immunogenicity by increasing the affinity of TG deter-
minants for the T cell receptor (Carayanniotis, 2011). Fur-
thermore, chronic high iodine exposure may induce
autoantigen presentation activity of thyrocytes and dendritic
cells as well as activate autoreactive T cells. Finally, excess
iodine-induced hypothyroidism in HT may be due to a
pathologically persistent inhibitory Wolff-Chaikoff effect
on thyroid hormone synthesis (Markou et al., 2001).
Selenium status. Selenium status is an important parameter
of general population health, and it has been hypothesised
that nutritional selenium deficiency may trigger the initia-
tion or progression of thyroid autoimmunity. Various ef-
fects of selenium are recognised, ranging from antioxidant
and anti-inflammatory to the production of active thyroid
hormone (Rayman, 2012). The amino acid selenocysteine is
a major form of thyroid selenium presented either by en-
zymes such as glutathione peroxidases (GPx), thioredoxin
reductases, iodothyronine deiodinases or proteins without
enzymatic function, known as selenoproteins (SELENO) P,
M, S (Valea et al., 2018). Enzyme proteins have an impor-
tant role in protecting thyrocytes from oxidative damage
and, also, in thyroid hormone metabolism. GPx provide thy-
roid antioxidant protection against free radicals and oxida-
tive stress, catalysing the detoxification of hydrogen perox-
ide and organic hydroperoxides. The biomarkers of
selenium status and function available for human studies in-
clude GPx3 (10–25% of plasma selenium), SELENOP
(20–70% of plasma selenium), and GPx1, which can be as-
sayed in erythrocytes, lymphocytes as well as tissue biopsy
specimens (Combs, 2015). GPx3 is also secreted at the api-
cal pole of the thyrocyte, where it degrades excess hydrogen
peroxide that has not been used by thyroid peroxidase,
whereas SELONOP, the major selenoprotein in plasma, is
crucial for the specific distribution and transport of sele-
nium to several target tissues. Studies in many countries
have shown the effects of geographic variation in the sele-
nium contents in food and plasma selenium concentrations
in different populations around the world.
Selenium deficiency has been recognised in several patho-
logical thyroid conditions including nodular goiter, thyroid
cancer, and AITD. Serum selenium levels have been shown
to be lower in newly diagnosed GD patients compared to
healthy subjects (Bülow Pedersen et al., 2013). Lower sele-
nium levels were evidenced in GD subjects compared to
those without this disease, suggesting that relative selenium
deficiency may be an independent risk factor contributing to
the development of orbitopathy in GD patients (Khong et
al., 2014). It is also well known that selenium supplementa-
tion is recommended to prevent progression of mild GO.
Selenium levels have been shown to be lower in patients
with HT as well. A recent cross-sectional study involving
more than six thousand participants from two provinces in
China that had high genetic, environmental, lifestyle as well
as iodine status similarities, except for very different soil-
selenium concentrations, revealed an increased prevalence
of HT but not GD in the province with lower selenium in-
take (Wu et al., 2015).
Analysis of selenium status in HT and GD patients suggests
that supplementation of this trace element may be beneficial
in these patients. It has been observed that selenium supple-
mentation decreases TPOAb levels more effectively in indi-
viduals with a lower baseline level (Toulis et al., 2010).
Furthermore, regions with deficient, higher than adequate or
high iodine intake may have more need for selenium
through its role within selenoproteins, protecting the thyroid
gland from oxidative damage as well as increasing immune
tolerance (Hu and Rayman, 2017). It has been also demon-
strated that selenium supplementation can upregulate Treg
cells that have been reduced by excess iodine intake (Xue et
al., 2015).
Reduction of circulating thyroid autoantibody levels by se-
lenium supplementation in individuals with HT was de-
scribed almost two decades ago. Over the last years, numer-
ous prospective clinical trials were performed to examine
whether selenium supplementation either with sodium se-
lenite or selenomethionine might have beneficial effects for
the treatment of HT. A meta-analysis published in 2016
showed that selenium supplementation effectively reduced
TPOAb levels at 3, 6, and 12 months in levothyroxine-
treated HT patients. Importantly, in untreated patients, there
was a decrease in TPOAb levels after 3 months, but not af-
ter 6 or 12 months of supplementation (Wichman et al.,
2016). Another meta-analysis study was published evaluat-
ing several types of the outcome, except for TPOAb levels
(Winther et al., 2017). It demonstrated that TSH and ultra-
sound finding improvement with selenium had a very low
to low level of evidence, while the quality of life improve-
ment had a low to moderate level of evidence. Although a
role for selenium supplementation in the treatment of HT is
still discrepant, the correction of a selenium deficiency may
have other health benefits. It is highly important to assess
patients’ selenium status before and during selenium ad-
ministration as well as to identify and correct selenium defi-
ciency in these patients. However, it remains unclear how
selenium supplementation may affect HT in patients with
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higher baseline selenium intake. Further randomised con-
trolled trials are required before selenium supplementation
can be routinely suggested by clinicians in patients with
HT.
Stress as a trigger. According to studies and observations,
stress does not have any triggering role in HT. However,
among the non-genetic factors involved in GD, one is stress.
Despite several retrospective case-control studies, which
found a higher frequency of stressful life events in the year
preceding the primarily diagnosed GD, the role of stress as
a trigger still remains controversial. A prospective study by
Effraimidis et al. with a five-year follow-up period did not
detect any causal relationship between stressful life events
and GD (Effraimidis et al., 2011). In contrast, a role of
stress in triggering both the onset and the recurrences of hy-
perthyroidism in patients with GD was highlighted by con-
tinued follow-up for 5 years after antithyroid drug with-
drawal (Vita et al., 2014). Stress may affect the immune
system both directly and indirectly through the activation of
nervous and endocrine systems. Activation of the hypotha-
lamic-pituitary-adrenal axis and the sympathoadrenal sys-
tem occurs under exposure to stress causes enhanced secre-
tion of glucocorticoids and catecholamines, which both
have a similar immunomodulatory effect and are consistent
with an imbalance in favour of Th2 cells. Hormones sup-
press the production of IL-2 by antigen-presenting cells and
increase the secretion of IL-4 and IL-10 by Th2 cells, di-
recting the immunity toward a Th2 response (Chrousos and
Elenkov, 2006). In addition, the decrease in DHEA during
stress can also stimulate a Th2-type immunity. Altogether,
this may promote the development of GD, which is consid-
ered to be a Th2-dependent disease. However, recent stud-
ies provide evidence for the presence and role of Th17 cells
in the pathogenesis of GD. Interestingly, it has been shown
that female C57BL/6 mice under chronic exposure to stress
demonstrate a shift toward proinflammatory Th1/Th17 ver-
sus Th2 responses (Harpaz et al., 2013).
Immune-related thyroiditis. Drugs such as amiodarone,
lithium, and biological agents can contribute to the manifes-
tation of AITD via immune mediated effects or direct ef-
fects of drugs on the thyroid. Biological agents are widely
used in the treatment of cancer, nonmalignant diseases, and
several autoimmune disorders. Indeed, the reported inci-
dence of de novo development of thyroid autoantibodies in
hepatitis C patients treated with IFN varied in studies from
2% to 40% (Mandac et al., 2006). IFN-related thyro-
toxicosis in more than 50% of these patients was due to de-
structive thyroiditis, while in the remainder due to GD. In-
terestingly, a recent review showed that treatment with
biological antirheumatic agents (TNF- inhibitors and
rituximab) did not seem to induce or worsen AITD in rheu-
matoid arthritis patients (Bliddal et al., 2017). However, the
monitoring of thyroid status is recommended due to the
well-established association between rheumatoid arthritis
and AITD. Similarly, in patients with inflammatory bowel
disease, there was no change regarding thyroid autoanti-
bodies after treatment with anti-TNF (Paschou et al., 2018).
Immune checkpoint inhibitors (ICPi) (anti-CTLA4 and
anti-PD1 therapy), which are widely used in cancer therapy,
can also trigger thyroiditis. However, ICPi-related thyroid
dysfunction is typically due to destructive thyroiditis, which
manifests as thyrotoxicosis followed by the transition to
hypothyroidism. The role of antibodies in the pathophysio-
logy of ICPi-related thyroiditis remains unclear (Priyanka et
al., 2018; Chang et al., 2019). The reported prevalence of
TPOAb/TgAb positivity is relatively low, and only two
cases of ICPi-related GD have been reported. Furthermore,
the de novo development of thyroid autoantibodies might be
due to humoral response to the exposure of antigens caused
by a destructive thyroiditis. Therefore, routine monitoring
of TPOAb/TgAb has not been demonstrated to be helpful
(Chang et al., 2019).
CONCLUSIONS
Although AITD present with two pathogenetically and
clinically different pathologies, the cellular and humoral im-
mune responses implicated in HT and GD are closely con-
nected and cross-linked. Despite comprehensive research in
the last decades, the specific immunological mechanisms of
the initiation and progression of thyroid autoimmunity re-
main unclear. Numerous recent studies have highlighted an
essential pro-inflammatory role of a new subset of the Th
cells, designated Th17, in the pathogenesis of AITD, thus
changing the traditional paradigm of Th1/Th2 dichotomy. It
has been found that Th17-lineage is heterogeneous, exhibit-
ing under certain cytokine exposure two different cellular
phenotypes: pathogenic and non-pathogenic. On the other
hand, Treg cells are responsible for the maintenance of
self-tolerance, thus protecting against thyroid autoimmu-
nity. An altered balance between Th17 cells and Treg as
well as Treg cell dysfunction has been found in AITD. Fu-
ture studies highlighting the role of Th17 in autoimmune in-
flammation are highly required. Evaluation of different T
cell subsets linked to certain cytokine production in AITD
could help identify the immune mechanisms involved in
thyroid autoimmunity, thus deepening our knowledge about
disease outcome and treatment strategies. Many environ-
mental factors can influence the development of AITD, in-
cluding increased iodine intake, selenium deficiency and
stress. The mechanisms of the interaction between genetic
and environmental factors also deserve further investiga-
tion, which will have a significant impact on the prevention
of AITD. Therefore, it is critical to investigate the possible
interplay of environmental and genetic factors as well as to
identify the possible mechanisms and immunomodulating
effects of environmental factors involved in thyroid autoim-
munity, to propose individualised AITD management
strategies, since most environmental factors may be modi-
fied.
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AUTOIMÛNO VAIROGDZIEDZERA SLIMÎBU IMUNOLOÌISKIE MEHÂNISMI: TRADICIONÂLÂS TH1/TH2 PARADIGMAS
MAIÒA
Autoimûnâs vairogdziedzera slimîbas ietver Hasimoto tireoidîtu (HT) un Greivsa slimîbu (GS), kuras raksturo asinîs cirkulçjoðas antivielas
pret daþâdiem vairogdziedzera autoantigçniem un vairogdziedzera audu infiltrâcija ar autoreaktîviem limfocîtiem. Lai gan pçdçjo desmit gadu
laikâ sasniegts neizmçrojams progress vairogdziedzera autoimûno slimîbu patoìençzes izpratnç, tomçr detalizçts slimîbu attîstîbas
imunoloìiskais mehânisms joprojâm pilnîbâ nav skaidrs. Pieòemts uzskatît, ka HT attîstîbu nosaka 1. tipa T lîdzçtâjðûnas (Th1), bet GS
attîstâs pa Th2 ðûnu determinçto autoimûnâs reakcijas patoìençzes ceïu. Ðo tradicionâlo pieòçmumu mainîjuði pierâdîjumi par Th17 ðûnu
lomu vairogdziedzera autoimûno slimîbu attîstîbâ, galvenokârt HT patoìençzç. Jâuzsver, ka attîstoties autoimûnajam procesam, izzûd
lîdzsvars regulatoro T ðûnu un Th17 limfocîtu starpâ. Savos iepriekð veiktajos pçtîjumos GS un HT pacientu vairogdziedzera audos esam
pierâdîjuði pastiprinâtu IL-17 ekspresiju, kas ir Th17 ðûnu galvenais efektorais citokîns. Ðajâ literatûras apskatâ galvenokârt analizçta
regulatoro T un Th17 ðûnu loma autoimûno vairogdziedzera slimîbu patoìençzç. Tâpat apskatîta svarîgâko ârvides faktoru nozîme un
mehânismi autoimûno slimîbu izcelsmç, kas ir svarîgi arî Latvijas kontekstâ.
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